Progyny Appoints Two Renowned Women’s Health Experts to Medical Advisory Board
Rhea-AI Summary
Progyny (NASDAQ: PGNY), a leading women's health and family building solutions provider, has strengthened its Medical Advisory Board with two distinguished appointments. Dr. Gloria Richard-Davis from Morehouse School of Medicine and Dr. Whitney Booker from Columbia University join the board, bringing extensive expertise in women's health and reproductive medicine.
Dr. Richard-Davis is double-board certified in OB-GYN and Reproductive Endocrinology and Infertility, with significant experience in menopause care and health equity. Dr. Booker, double-board certified in OB-GYN and Maternal-Fetal Medicine, specializes in high-risk maternal care and prenatal fetal diagnosis, with NIH-funded research focusing on hypertension and cardiovascular disease in pregnancy.
Positive
- None.
Negative
- None.
News Market Reaction – PGNY
In the trading session that priced this news, PGNY gained 0.83%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Medical Advisory Board additions support company’s growing product offerings across women’s health and family building
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced the appointment of Morehouse School of Medicine’s Regional Dean for Seattle and Puget Sound’s Dr. Gloria Richard-Davis – a double-board certified physician in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, a fellow of the American College of Obstetricians & Gynecologists (FACOG), and a Menopause Society Certified Practitioner (MSCP) – and Columbia University’s Dr. Whitney Booker – a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine – to its Medical Advisory Board.
“As Progyny continues to be at the forefront of women’s health, we are proud to welcome two deeply respected clinical leaders whose unique training and lived experience will bring critical insights to our work,” said Dr. Janet Choi, Chief Medical Officer at Progyny. “Dr. Richard-Davis and Dr. Booker have spent their careers advancing care, health equity, and research in fertility, maternal health, and beyond – their individual expertise will complement our board as we continue to expand across the women’s health spectrum.”
Dr. Gloria Richard-Davis is a nationally recognized leader in women’s health and reproductive medicine, with deep expertise in advancing health equity across academic, clinical, and organizational settings. She is a member of The Endocrine Society, Society of Reproductive Endocrinologists, American Medical Association, among others. She completed her OB-GYN residency at Madigan Army Medical Center and advanced training in fertility and reproductive endocrinology. Her academic career includes leadership roles at Tulane University, Meharry Medical College, and the University of Arkansas for Medical Sciences. She has also held multiple leadership roles within the Menopause Society (formerly North American Menopause Society) and the American Society for Reproductive Medicine (ASRM) and is a recipient of the ASRM Gold Humanitarian Practitioner Award.
“I’ve dedicated my career to advancing access and education in women’s health, particularly in areas like menopause that have long been overlooked,” said Dr. Richard-Davis. “Progyny is raising the bar for how fertility and menopause benefits can address whole-person care, and I’m proud to be part of this team changing the lives of so many individuals.”
Dr. Whitney A. Booker is a double-board certified physician in Obstetrics and Gynecology and Maternal-Fetal Medicine, nationally recognized for her work in prenatal fetal diagnosis and high-risk maternal care. She is an expert in advanced ultrasound imaging, prenatal genetic testing, and managing pregnancies complicated by rare maternal conditions. Dr. Booker is also a physician-scientist, with NIH and university grant funding supporting her research into hypertension and cardiovascular disease in pregnancy. She brings expertise in treating pregnancies conceived through IVF and in advanced maternal age.
“Progyny is changing the way care is delivered across the full parenting journey by partnering with trained specialists and delivering high-touch, personalized support to each of its members,” said Dr. Booker. “I see firsthand the impact of comprehensive support for high-risk pregnancies, and I look forward to bringing my unique insights in this area to Progyny’s Medical Advisory Board to help meet the needs of these women and families.”
For more information on Progyny visit www.progyny.com and for more information on its Medical Advisory Board visit www.progyny.com/medical-advisory-board/.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Media:
Alexis Ford
media@progyny.com
Investors:
James Hart
investors@progyny.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f685a60-ac4b-4dd8-ac77-8ae2d0822fa9
